Antihistamine use may improve oncologic and survival outcomes in patients receiving second-line atezolizumab for advanced or metastatic urothelial carcinoma, according to research published in ...

Credit: Thinkstock Investigators explored the potential of a noninvasive ctDNA assay as a predictive biomarker for advanced or metastatic urothelial cancer. Increases in circulating tumor DNA ...

Background: Abnormal extracellular matrix (ECM) remodeling plays an essential role in urothelial carcinoma (UC) invasiveness and metastasis. Focusing on the ECM structural constituent (GO: 0005201), ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular carcinoma, ovarian cancer and lung adenocarcinoma ...

Bladder cancers comprise heterogeneous cell populations, and numerous factors are likely to be involved in dictating recurrence, progression and patient survival. While several molecular markers ...

Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today ...

You will be redirected to our submission process. Urothelial carcinoma (UC), which includes both bladder cancer and upper tract urothelial carcinoma (UTUC), remains one of the most aggressive and ...

The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least FGFR3 testing to help ...

Disitamab vedotin is under clinical development by Pfizer and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic ...

Fibroblast growth factor receptors (FGFRs) are critical drivers of oncogenesis in various solid tumors, including urothelial carcinoma, hepatocellular ...